ArticleFrontiers in immunology2018
A Web Resource for Designing Subunit Vaccine Against Major Pathogenic Species of Bacteria.
Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Development of a novel multi-epitope vaccine against Ureaplasma urealyticum infection through reverse vaccinology approach.Molecular diversity · 2026Article
- Article
- Safety and efficacy of aJournal of veterinary science · 2025Article
- Revolutionizing Nanovaccines: A New Era of Immunization.Vaccines · 2025Review
- Rational design of an epitope-centric vaccine againstFrontiers in immunology · 2025Article
- Rational Design of an Epidermal Growth Factor Receptor Vaccine: Immunogenicity and Antitumor Research.Biomolecules · 2024Article
- Article
- A Web-Based Method for the Identification of IL6-Based Immunotoxicity in Vaccine Candidates.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Immunoinformatics and reverse vaccinology approach in designing a novel highly immunogenic multivalent peptide-based vaccine against the human monkeypox virus.Frontiers in molecular biosciences · 2023Article
- Integration of immunoinformatics and cheminformatics to design and evaluate a multitope vaccine againstFrontiers in molecular biosciences · 2023Article
- Identification of a Potential Vaccine againstVaccines · 2022Article
- Subtractive proteomics assisted therapeutic targets mining and designing ensemble vaccine against Candida auris for immune response induction.Computers in biology and medicine · 2022Article
- Recent developments in systems biology and genetic engineering toward design of vaccines for TB.Critical reviews in biotechnology · 2022Review
- CD8TCEI-EukPath: A Novel Predictor to Rapidly Identify CD8Frontiers in genetics · 2022Article
- Subtractive Proteomics and Immuno-informatics Approaches for Multi-peptide Vaccine Prediction AgainstInternational journal of peptide research and therapeutics · 2021Article
- Design of a multi-epitope subunit vaccine for immune-protection against Leishmania parasite.Pathogens and global health · 2020Article
- Novel Chimeric Multiepitope Vaccine for Streptococcosis Disease in Nile Tilapia (Oreochromis niloticus Linn.).Scientific reports · 2020Article
- Prediction of Burkholderia pseudomallei DsbA substrates identifies potential virulence factors and vaccine targets.PloS one · 2020Article
- EpitoCore: Mining Conserved Epitope Vaccine Candidates in the Core Proteome of Multiple Bacteria Strains.Frontiers in immunology · 2020Article
- PRRDB 2.0: a comprehensive database of pattern-recognition receptors and their ligands.Database : the journal of biological databases and curation · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evolution has led to the expansion of survival strategies in pathogens including bacteria and emergence of drug resistant strains proved to be a major global threat. Vaccination is a promising strategy to protect human population. Reverse vaccinology is a more robust vaccine development approach especially with the availability of large-scale sequencing data and rapidly dropping cost of the techniques for acquiring such data from various organisms. The present study implements an immunoinformatic approach for screening the possible antigenic proteins among various pathogenic bacteria to systemically arrive at epitope-based vaccine candidates against 14 pathogenic bacteria. Thousand four hundred and fifty nine virulence factors and Five hundred and forty six products of essential genes were appraised as target proteins to predict potential epitopes with potential to stimulate different arms of the immune system. To address the self-tolerance, self-epitopes were identified by mapping on 1000 human proteome and were removed. Our analysis revealed that 21proteins from 5 bacterial species were found as virulent as well as essential to their survival, proved to be most suitable vaccine target against these species. In addition to the prediction of MHC-II binders, B cell and T cell epitopes as well as adjuvants individually from proteins of all 14 bacterial species, a stringent criteria lead us to identify 252 unique epitopes, which are predicted to be T-cell epitopes, B-cell epitopes, MHC II binders and Vaccine Adjuvants. In order to provide service to scientific community, we developed a web server VacTarBac for designing of vaccines against above species of bacteria. This platform integrates a number of tools that includes visualization tools to present antigenicity/epitopes density on an antigenic sequence. These tools will help users to identify most promiscuous vaccine candidates in a pathogenic antigen. This server VacTarBac is available from URL (http://webs.iiitd.edu.in/raghava/vactarbac/).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.